Alpha-lipoic acid decreases hepatic lipogenesis through adenosine monophosphate-activated protein kinase (AMPK)-dependent and AMPK-independent pathways

Hepatology

Volumn 48, Issue 5, 2008, Pages 1477-1486

  Park, Keun Gyu ^a   Min, Ae Kyung ^a   Koh, Eun Hee ^b   Kim, Hyoun Sik ^b   Kim, Mi Ok ^b   Park, Hye Sun ^b   Kim, Yong Deuk ^c   Yoo, Tae Seung ^a   Jang, Byoung Kuk ^a   Hwang, Jae Seok ^a   Kim, Jae Bum ^d   Choi, Hueng Sik ^e   Park, Joong Yeol ^b   Lee, In Kyu ^c   Lee, Ki Up ^b  

^a Keimyung University School of Medicine   (South Korea)

^b University of Ulsan College of Medicine   (South Korea)

^c Kyungpook National University School of Medicine   (South Korea)

^d Seoul National University   (South Korea)

^e Chonnam National University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE KINASE; INSULIN; LIVER X RECEPTOR; LIVER X RECEPTOR AGONIST; STEROL REGULATORY ELEMENT BINDING PROTEIN 1C; THIOCTIC ACID; TRIACYLGLYCEROL; AMP ACTIVATED PROTEIN KINASES; AMP-ACTIVATED PROTEIN KINASES; LIPID; MESSENGER RNA; MULTIENZYME COMPLEX; PROTEIN SERINE THREONINE KINASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DNA BINDING; DRUG MECHANISM; GENE EXPRESSION; HUMAN; HUMAN CELL; INSULIN RESISTANCE; INSULIN SENSITIVITY; LIPID DIET; LIPID STORAGE; LIPOGENESIS; LIVER WEIGHT; MALE; MOUSE; NONALCOHOLIC FATTY LIVER; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RAT; TRIACYLGLYCEROL BLOOD LEVEL; BIOSYNTHESIS; DRUG EFFECT; ENZYME ACTIVATION; ENZYMOLOGY; FATTY LIVER; GENETICS; KINETICS; LIVER; LIVER CELL CARCINOMA; LIVER TUMOR; METABOLISM; OBESITY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TUMOR CELL LINE;

CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; ENZYME ACTIVATION; FATTY LIVER; HUMANS; INSULIN RESISTANCE; KINETICS; LIPIDS; LIVER; LIVER NEOPLASMS; MULTIENZYME COMPLEXES; OBESITY; PROTEIN-SERINE-THREONINE KINASES; RNA, MESSENGER; THIOCTIC ACID; TRIGLYCERIDES;

EID: 56149098763     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22496     Document Type: Article

References (29)

1. Marceau P, Biron S, Hould FS, Marceau S, Simard S, Thung SN, et al. Liver pathology and the metabolic syndrome X in severe obesity. J Clin Endocrinol Metab 1999;84:1513-1517.
2. Marchesini G, Brizi M, Bianchi G, Tomassetti S, Bugianesi E, Lenzi M, et al. Nonalcoholic fatty liver disease, a feature of the metabolic syndrome. Diabetes 2001;50:1844-1850.
3. Horton JD. Sterol regulatory element-binding proteins: Transcriptional activators of lipid synthesis. Biochem Soc Trans 2002;30:1091-1095.
4. Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, et al. Weight-reducing effects of the plasma protein encoded by the obese gene. Science 1995;269:543-546.
5. Yahagi N, Shimano H, Hasty AH, Matsuzaka T, Ide T, Yoshikawa T, et al. Absence of sterol regulatory element-binding protein-1 (SREBP-1) ameliorates fatty livers but not obesity or insulin resistance in Lepob/ Lepob mice. J Biol Chem 2002;277:19353-19357.
6. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, et al. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 2001;108:1167-1174.
7. Bajaj M, Suraamornkul S, Pratipanawatr T, Hardies LJ, Pratipanawatr W, Glass L, et al. Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 2003; 52:1364-1370.
8. Deng X, Yellaturu C, Cagen L, Wilcox HG, Park EA, Raghow R, et al. Expression of the rat sterol regulatory element-binding protein-1c gene in response to insulin is mediated by increased transactivating capacity of specificity protein 1 (Sp1). J Biol Chem 2007;15:17517-17529.
9. Cagen LM, Deng X, Wilcox HG, Park EA, Raghow R, Elam MB. Insulin activates the rat sterol-regulatory-element-binding protein 1c (SREBP-1c) promoter through the combinatorial actions of SREBP, LXR, Sp-1 and NF-Y cis-acting elements. Biochem J 2005;385:207-216.
10. Lee WJ, Song KH, Koh EH, Won JC, Kim HS, Park HS, et al. Alphalipoic acid increases insulin sensitivity by activating AMPK in skeletal muscle. Biochem Biophys Res Commun 2005;332:885-891.
11. Lee Y, Naseem RH, Park BH, Garry DJ, Richardson JA, Schaffer JE, et al. Alpha-lipoic acid prevents lipotoxic cardiomyopathy in acyl CoA-synthase transgenic mice. Biochem Biophys Res Commun 2006;344:446-452.
12. Targonsky ED, Dai F, Koshkin V, Karaman GT, Gyulkhandanyan AV, Zhang Y, et al. Alpha-lipoic acid regulates AMP-activated protein kinase and inhibits insulin secretion from beta cells. Diabetologia 2006;49:1587-1598.
13. Lee KU, Park JY, Kim CH, Hong SK, Suh KI, Park KS, et al. Effect of decreasing plasma free fatty acids by acipimox on hepatic glucose metabolism in normal rats. Metabolism 1996;45:1408-1414.
14. Oakes ND, Cooney GJ, Camilleri S, Chisholm DJ, Kraegen EW. Mechanisms of liver and muscle insulin resistance induced by chronic high-fat feeding. Diabetes 1997;46:1768-1774.
15. Woods A, Azzout-Marniche D, Foretz M, Stein SC, Lemarchand P, Ferre P, et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol Cell Biol 2000;20:6704-6711.
16. Dyck JR, Gao G, Widmer J, Stapleton D, Fernandez CS, Kemp BE, et al. Regulation of 5′-AMP-activated protein kinase activity by the noncatalytic beta and gamma subunits. J Biol Chem 1996;271:17798-17803.
17. Kim MS, Park JY, Namkoong C, Jang PG, Ryu JW, Song HS, et al. Anti-obesity effects of alpha-lipoic acid mediated by suppression of hypothalamic AMP-activated protein kinase. Nat Med 2004;10:727-733.
18. Foretz M, Guichard C, Ferré P, Foufelle F. Sterol regulatory element binding protein-1c is a major mediator of insulin action on the hepatic expression of glucokinase and lipogenesis-related genes. Proc Natl Acad Sci U S A 1999;96:12737-12742.
19. Chen G, Liang G, Ou J, Goldstein JL, Brown MS. Central role for liver X receptor in insulin-mediated activation of Srebp-1c transcription and stimulation of fatty acid synthesis in liver. Proc Natl Acad Sci U S A 2004;101: 11245-11250.
20. Miao B, Zondlo S, Gibbs S, Cromley D, Hosagrahara VP, Kirchgessner TG, et al. Raising HDL cholesterol without inducing hepatic steatosis and hypertriglyceridemia by a selective LXR modulator. J Lipid Res 2004;45: 1410-1417.
21. Dicter N, Madar Z, Tirosh O. Alpha-lipoic acid inhibits glycogen synthesis in rat soleus muscle via its oxidative activity and the uncoupling of mitochondria. J Nutr 2002;132:3001-3006.
22. Lee WJ, Lee IK, Kim HS, Kim YM, Koh EH, Won JC, et al. Alpha-lipoic acid prevents endothelial dysfunction in obese rats via activation of AMP-activated protein kinase. Arterioscler Thromb Vasc Biol 2005;25:2488-2494.
23. Zelcer N, Tontonoz P. Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 2006;116:607-614.
24. Browning JD, Horton JD. Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 2004;114:147-152.
25. Jacob S, Ruus P, Hermann R, Tritschler HJ, Maerker E, Renn W, et al. Oral administration of RAC-alpha-lipoic acid modulates insulin sensitivity in patients with type-2 diabetes mellitus: A placebo-controlled pilot trial. Free Radic Biol Med 1999;27:309-314.
26. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med 2002;346:1221-1231.
27. Dixon JB, Bhathal PS, O'Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology 2001;121:91-100.
28. Ratziu V, Bonyhay L, Di Martino V, Charlotte F, Cavallaro L, Sayegh-Tainturier MH, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. HEPATOLOGY 2002;35:1485-1493.
29. Ametov AS, Barinov A, Dyck PJ, Hermann R, Kozlova N, Litchy WJ, et al. The sensory symptoms of diabetic polyneuropathy are improved with alpha- lipoic acid: The SYDNEY trial. Diabetes Care 2003;26:770-776.